Implante intravítreo de fluocinolona

Tratamiento del edema macular diabético

Comparación de la función visual y mejora estructural en ojos pseudofáquicos con edema macular diabético tratados con implante intravítreo de 0,19 mg fluocinolona acetónida, en la práctica profesional.

Autor/a: William Fusi-Rubiano, Chandoshi Mukherjee, Mark Lane y colaboradores

Fuente: BMC Ophthalmology (2018) 18:62

Indice
1. Referencias bibliográficas
2. Página 1

1. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

2. Lee R, Wong TY, Sabanayagam C. Epidemiology of diabetic retinopathy, diabetic macula edema and related vision loss. Eye Vis (lond). 2015;2:17.

3. Romero-Aroca P. Managing diabetic macular edema: The leading cause of diabetes blindness. World Journal of Diabetes. 2011;2(6):98–104.

4. Amoaku WM, Saker S, Stewart EA. A review of therapies for diabetic macular oedema and rationale for combination therapy. Eye. 2015;29(9):1115.

5. Klaassen I, Van Noorden CJ, Schlingemann RO. Molecular basis of the inner blood–retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res. 2013;34:19–48.

6. Ehrlich R, Harris A, Ciulla TA, Kheradiya N, Winston DM, Wirostko B. Diabetic macular oedema: physical, physiological and molecular factors contribute to this pathological process. Acta Ophthalmol. 2010;88:279–91.